Merus N.V. NASDAQ:MRUS

Merus N.V. stock price today

$64.23
+22.16
+52.67%
Financial Health
0
1
2
3
4
5
6
7
8
9

Merus N.V. stock price monthly change

-26.53%
month

Merus N.V. stock price quarterly change

-26.53%
quarter

Merus N.V. stock price yearly change

+47.25%
year

Merus N.V. key metrics

Market Cap
2.88B
Enterprise value
585.74M
P/E
-6.58
EV/Sales
14.19
EV/EBITDA
-12.71
Price/Sales
17.73
Price/Book
2.96
PEG ratio
-0.06
EPS
-2.72
Revenue
38.33M
EBITDA
-148.78M
Income
-149.65M
Revenue Q/Q
-41.55%
Revenue Y/Y
-11.72%
Profit margin
-119.3%
Oper. margin
-257.82%
Gross margin
0%
EBIT margin
-257.82%
EBITDA margin
-388.09%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Merus N.V. stock price history

Merus N.V. stock forecast

Merus N.V. financial statements

Average Price Target
Last Year

$81.25

Potential upside: 26.49%

Based on estimate of 4 analysts
  • Analysts Price target

  • Financials & Ratios estimates

Merus N.V. (NASDAQ:MRUS): Profit margin
Jun 2023 10.47M -32.03M -305.78%
Sep 2023 11.03M -23.01M -208.57%
Dec 2023 8.93M -60.15M -672.93%
Mar 2024 7.88M -34.45M -436.76%
Merus N.V. (NASDAQ:MRUS): Debt to assets
Jun 2023 363624000 106.21M 29.21%
Sep 2023 492186000 98.79M 20.07%
Dec 2023 458494000 102.15M 22.28%
Mar 2024 498083000 148.63M 29.84%
Merus N.V. (NASDAQ:MRUS): Cash Flow
Jun 2023 -41.58M -24.51M 65.96M
Sep 2023 -27.53M 8.02M 162.40M
Dec 2023 -34.88M -1.80M -1.24M
Mar 2024 -44.38M -12.07M 30.15M

Merus N.V. alternative data

Merus N.V. (NASDAQ:MRUS): Employee count
Aug 2023 164
Sep 2023 164
Oct 2023 164
Nov 2023 164
Dec 2023 164
Jan 2024 164
Feb 2024 164
Mar 2024 172
Apr 2024 172
May 2024 172
Jun 2024 172
Jul 2024 172

Merus N.V. other data

0.03% -79.22%
of MRUS is owned by hedge funds
12.02M -24.47M
shares is hold by hedge funds

Merus N.V. (NASDAQ:MRUS): Insider trades (number of shares)
Period Buy Sel
Dec 2023 0 23326
Jun 2024 0 86300
Transaction Date Insider Security Shares Price per share Total value Source
Option
SILVERMAN PETER B. officer: COO & GC Common Shares 7,453 $17.94 $133,707
Option
SILVERMAN PETER B. officer: COO & GC Common Shares 2,547 $17.94 $45,693
Option
SILVERMAN PETER B. officer: COO & GC Share Option (right to buy) 7,453 $17.94 $133,707
Sale
SILVERMAN PETER B. officer: COO & GC Common Shares 10,000 $60 $600,000
Sale
SILVERMAN PETER B. officer: COO & GC Common Shares 62,000 $56.52 $3,504,178
Option
SILVERMAN PETER B. officer: COO & GC Common Shares 9,253 $17.94 $165,999
Option
SILVERMAN PETER B. officer: COO & GC Common Shares 2,747 $17.94 $49,281
Option
SILVERMAN PETER B. officer: COO & GC Common Shares 41,577 $25.9 $1,076,844
Option
SILVERMAN PETER B. officer: COO & GC Common Shares 8,423 $25.9 $218,156
Option
SILVERMAN PETER B. officer: COO & GC Share Option (right to buy) 9,253 $17.94 $165,999
Monday, 16 December 2024
globenewswire.com
Saturday, 7 December 2024
globenewswire.com
Thursday, 5 December 2024
benzinga.com
Wednesday, 4 December 2024
globenewswire.com
Monday, 2 December 2024
globenewswire.com
Sunday, 1 December 2024
globenewswire.com
Thursday, 21 November 2024
schaeffersresearch.com
Wednesday, 6 November 2024
globenewswire.com
Tuesday, 5 November 2024
seekingalpha.com
globenewswire.com
Thursday, 31 October 2024
zacks.com
globenewswire.com
Wednesday, 14 August 2024
seekingalpha.com
Thursday, 1 August 2024
zacks.com
globenewswire.com
Monday, 29 July 2024
zacks.com
Wednesday, 24 July 2024
globenewswire.com
Monday, 3 June 2024
globenewswire.com
Sunday, 2 June 2024
globenewswire.com
Wednesday, 29 May 2024
globenewswire.com
globenewswire.com
Tuesday, 28 May 2024
globenewswire.com
globenewswire.com
Monday, 27 May 2024
zacks.com
Friday, 24 May 2024
seekingalpha.com
Thursday, 23 May 2024
globenewswire.com
globenewswire.com
Monday, 13 May 2024
globenewswire.com
Wednesday, 8 May 2024
globenewswire.com
Monday, 6 May 2024
globenewswire.com
  • What's the price of Merus N.V. stock today?

    One share of Merus N.V. stock can currently be purchased for approximately $64.23.

  • When is Merus N.V.'s next earnings date?

    Unfortunately, Merus N.V.'s (MRUS) next earnings date is currently unknown.

  • Does Merus N.V. pay dividends?

    No, Merus N.V. does not pay dividends.

  • How much money does Merus N.V. make?

    Merus N.V. has a market capitalization of 2.88B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 5.68% to 43.95M US dollars.

  • What is Merus N.V.'s stock symbol?

    Merus N.V. is traded on the NASDAQ under the ticker symbol "MRUS".

  • What is Merus N.V.'s primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Merus N.V.?

    Shares of Merus N.V. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Merus N.V.'s key executives?

    Merus N.V.'s management team includes the following people:

    • Dr. Sven Ante Lundberg Chief Executive Officer, Pres, Principal Financial Officer & Executive Director(age: 62, pay: $986,820)
    • Mr. Peter B. Silverman J.D. Executive Vice President, Gen. Counsel, Chief Intellectual Property Officer and Head of Utrecht & US Legal(age: 47, pay: $614,880)
    • Mr. Hui Liu Chief Bus. Officer, Executive Vice President & Head of Merus U.S.(age: 58, pay: $611,310)
  • How many employees does Merus N.V. have?

    As Jul 2024, Merus N.V. employs 172 workers.

  • When Merus N.V. went public?

    Merus N.V. is publicly traded company for more then 9 years since IPO on 19 May 2016.

  • What is Merus N.V.'s official website?

    The official website for Merus N.V. is merus.nl.

  • How can i contact Merus N.V.?

    Merus N.V. can be reached via phone at +31 30 253 8800.

  • What is Merus N.V. stock forecast & price target?

    Based on 4 Wall Street analysts` predicted price targets for Merus N.V. in the last 12 months, the avarage price target is $81.25. The average price target represents a 26.49% change from the last price of $64.23.

Merus N.V. company profile:

Merus N.V.

merus.nl
Exchange:

NASDAQ

Full time employees:

172

Industry:

Biotechnology

Sector:

Healthcare

Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

Yalelaan 62
Utrecht, 3584 CM

CIK: 0001651311
ISIN: NL0011606264
CUSIP: N5749R100